LUCCA, ITALY, May 14, 2007-Acceleron Pharma, Inc., a
biopharmaceutical company developing therapeutics for the treatment
of musculoskeletal, metabolic and cancer-related diseases, today
announced results of a preclinical study with ACE-031 that
demonstrated the ability of the compound to increase muscle mass
and strength in normal mice and in murine models of muscular
dystrophy. ACE-031 inhibits negative regulators of muscle to
increase muscle mass and strength as a potential treatment for
neuromuscular diseases and cancer-related muscle loss. The data was
presented on Sunday, May 13 at the Gordon Research Conference on
Myogenesis in Lucca, Italy. ³
Acceleron is encouraged by the significant outcomes and positive data generated by ACE-031 spanning numerous preclinical models of muscle loss², said Jas Seehra, Ph.D., Chief Scientific Officer of Acceleron. ³ACE-031 and related Acceleron compounds consistently demonstrate substantial increases in skeletal muscle mass and strength.² ACE-031, a protein therapeutic based on the activin receptor type IIB (ActRIIB), is the first of several compounds Acceleron is developing for the treatment of diseases involving the loss of muscle mass, strength and function. ActRIIB binds to myostatin (GDF-8) and other negative regulators of muscle mass and strength. Over-expression of myostatin has been shown to cause a loss in muscle mass and strength, and inhibition of myostatin results in the selective increase in skeletal muscle mass and strength. In preclinical models, ACE-031 increased skeletal muscle mass and strength in disease models of amyotrophic lateral sclerosis (ALS), muscular dystrophy, glucocorticoid-induced muscle loss and age-related muscle loss (sarcopenia).
ACE-031 offers the potential for an entirely new type of therapy for the treatment of various muscle wasting conditions. ³The clinical potential of ACE-031 to selectively increase skeletal muscle will offer a growing number of patients an excellent opportunity to benefit from a promising therapy for the otherwise untreatable muscle loss associated with their disease,² said Matthew L. Sherman, M.D., Chief Medical Officer of Acceleron. ³
Based on the comprehensive preclinical program currently underway, Acceleron is working toward advancing ACE-031 into Phase 1 clinical trials later this year.² Study Findings The presentation, entitled ³Treatment with a Soluble Activin Receptor IIB Causes Increased Muscle Mass and Strength in mdx Mice² discussed data from preclinical studies in normal mice and in a mouse model of muscular dystrophy. These studies show a substantial increase in muscle mass and a dose-dependent increase in lean body mass in treated animals. These effects are significant in just two weeks following start of therapy and increase further as treatment continues. In the mdx murine model of muscular dystrophy, treated animals showed increases in muscle mass which translated into significantly increased muscle strength.
About Muscle Loss
Loss of muscle mass and strength is a serious clinical consequence of several types of diseases and conditions: (1) neuromuscular diseases, such as ALS and muscular dystrophy, in which patients suffer from the loss of muscle strength and function which ultimately leads to respiratory failure and death (2) cancer-cachexia, in which patients can lose muscle mass and body weight as a result of both their cancer treatments (hormone deprivation therapy causes loss of muscle) and the cancer itself (3) other cachexias, in which the muscle loss is associated with chronic diseases such as congestive heart failure, chronic obstructive pulmonary disease, and chronic kidney disease and, (4) age-related muscle loss, known as sarcopenia, in which generalized muscle loss and frailty leads to frequent falls and morbidity and mortality from broken bones. A drug candidate that would increase muscle mass and strength is expected to produce a major clinical benefit across this broad range of serious medical conditions in which there are currently no safe and effective therapies that selectively increase skeletal muscle mass and strength.
About Acceleron Pharma
Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron¹s scientific approach takes advantage of its unique insight on the regenerative powers of two protein families: the Growth and Differentiation Factor (GDF) and Bone Morphogenetic Protein (BMP) families. The company¹s lead program is an anabolic bone agent being developed to reverse bone loss in diseases such as osteoporosis and cancer. Additionally, the company is advancing several preclinical programs that increase muscle mass, control angiogenesis and inhibit fat accumulation. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company¹s internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron are Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures, Sutter Hill Ventures and Venrock.
Contact: Steven Ertel, Vice President, Business Development, Acceleron Pharma, tel: 617-520-1334 and Paul Kidwell (Media) Suda Communications, tel: 617-296-3854 Paul Kidwell 617.296.3854: Office 617.680.1088: Mobile